|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
Herein, we demonstrate a streamlined approach to effectively screen and determine the function of secreted proteins in islets, and identified C1ql3 as a putative contributor to reduced insulin secretion in obesity, linking C1ql3 to an increased susceptibility to type 2 diabetes.
|
31300714 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate a novel regulatory mechanism by which C1ql3/BAI3 signaling causes an impairment of insulin secretion from β-cells, possibly contributing to the progression of type 2 diabetes in obesity.
|
30228187 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
We sought to investigate circulating CTRP1, CTRP9, CTRP12 and CTRP13 concentrations in persons with type 2 diabetes mellitus (T2DM), with age and BMI matched controls, and to examine the effects of a 2 hour 75g oral glucose tolerance test (OGTT) on serum CTRP1, CTRP9, CTRP12 and CTRP13 levels in persons with T2DM.
|
28207876 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
It appears that the decreased levels of CTRP3 and especially CTRP13 were associated with increased risk of T2DM and CAD.
|
28033351 |
2016 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Complement 1q like-3 (C1ql3) secreted protein was identified as a hub gene affecting islet function in obesity.
|
31300714 |
2019 |
|
Obesity
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Our aims were to examine whether the plasma levels of CTRP13 are (a) increased in patients with NAFLD; (b) associated with metabolic dysregulation, obesity, liver enzymes, and dyslipidemia; and (c) associated with putative symptoms of NAFLD.
|
30247335 |
2019 |
|
Obesity
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: Irrespective of obesity.
|
30540803 |
2018 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
C1q/tumor necrosis factor-related protein 13 (CTRP13) is a secreted adipokine that can ameliorate atherosclerosis and vascular calcification.
|
31676569 |
2020 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
C1q/tumor necrosis factor-related protein 13 (CTRP13) is a secreted adipokine that can ameliorate atherosclerosis and vascular calcification.
|
31676569 |
2020 |
|
Vascular calcification
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
C1q/tumor necrosis factor-related protein 13 (CTRP13) is a secreted adipokine that can ameliorate atherosclerosis and vascular calcification.
|
31676569 |
2020 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In summary, these findings define CTRP13 as a novel approach for preventing atherosclerotic plaque formation via modulation of lipid uptake and foam-cell migration.-Wang, C., Xu, W., Liang, M., Huang, D., Huang, K. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36.
|
30222079 |
2019 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In summary, these findings define CTRP13 as a novel approach for preventing atherosclerotic plaque formation via modulation of lipid uptake and foam-cell migration.-Wang, C., Xu, W., Liang, M., Huang, D., Huang, K. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36.
|
30222079 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we collected blood samples from patients of coronary artery diseases and apolipoprotein E (ApoE)<sup>-/-</sup> mice that were fed a Western diet for 12 wk to induce atherosclerosis and found that serum CTRP13 level was decreased.
|
30222079 |
2019 |
|
Vascular calcification
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In summary, these findings reveal that CTRP13 regulation is a novel method for the prevention of vascular calcification, representing a novel mechanism of the regulation of Runx2 expression in VSMCs.-Li, Y., Wang, W., Chao, Y., Zhang, F., Wang, C. CTRP13 attenuates vascular calcification by regulating Runx2.
|
31145871 |
2019 |
|
Coronary Artery Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we collected blood samples from patients of coronary artery diseases and apolipoprotein E (ApoE)<sup>-/-</sup> mice that were fed a Western diet for 12 wk to induce atherosclerosis and found that serum CTRP13 level was decreased.
|
30222079 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Association of C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 Serum Levels with Coronary Artery Disease in Subjects with and without Type 2 Diabetes Mellitus.
|
28033351 |
2016 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
It appears that the decreased levels of CTRP3 and especially CTRP13 were associated with increased risk of T2DM and CAD.
|
28033351 |
2016 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the role of CTRP13 in regulating endothelial function in diabetes has yet to be explored.
|
31676569 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
However, the role of CTRP13 in regulating endothelial function in diabetes has yet to be explored.
|
31676569 |
2020 |
|
Vascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, these results suggest that CTRP13 preserves endothelial function in diabetic mice by regulating GCH1/BH4 axis-dependent eNOS coupling, suggesting the therapeutic potential of CTRP13 against diabetic vasculopathy.
|
31676569 |
2020 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Kidney Failure, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that the serum CTRP13 levels were decreased in patients and rats with CRF and were negatively associated with calcium deposition in the abdominal aorta.
|
31145871 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |